Have you made your schedule for 2018? Take some time to consider your options and see what Ddu has planned this February!
Janssen’s Imbruvica will be routinely available on the NHS to treat certain patients with mantle cell lymphoma (MCL), after cost regulators issued a final green light for the drug.
The NHS 111 service has begun to incorporate AI technology.
NHS England has laid out plans for England to become the first country to eliminate hepatitis C, at least five years earlier than the World Health Organisation(WHO)’s target date of 2030.
The EMA has accepted the Marketing Authorization Application for romosozumab in the treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture.
Surgeons use Microsoft HoloLens headsets while operating on patients undergoing reconstructive lower limb surgery.
This year could see a transformation in the Japanese pharma market, according to a new report, with strong growth stemming from increased use of generics, biosimilars and stronger links with the global industry.
In many ways, 2017 was a banner year for digital health funding, according to Rock Health's annual report, which puts funding for the year at a record $5.8 billion.
Washington University School of Medicine sleep specialist Yo-El Ju, MD, led a research team that found circadian rhythm disruptions occur in people whose memories are intact but whose brain scans show early, preclinical evidence of Alzheimer's disease. She previously had discovered that people with clinical symptoms of Alzheimer's have disturbances in their internal body clocks that affect the sleep/wake cycle. Credit: Washington University School of Medicine.
Molecular Matrix Inc. invented a synthetic bone void filler, Osteo-P, that can help injured bones regrow.
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.